Shareholders Equity: The sum of preferred and common equity items.
Arcus Biosciences, Inc. (RCUS) had Shareholders Equity of $464.00M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$41.00M |
|
$-91.00M |
|
-- |
|
$41.00M |
|
$137.00M |
|
$-96.00M |
|
$5.00M |
|
$-91.00M |
|
$-91.00M |
|
$-91.00M |
|
$-91.00M |
|
$-91.00M |
|
$-91.00M |
|
$-96.00M |
|
$-96.00M |
|
126.10M |
|
126.10M |
|
$-0.72 |
|
$-0.72 |
|
| Balance Sheet Financials | |
$756.00M |
|
$36.00M |
|
$168.00M |
|
$924.00M |
|
$198.00M |
|
$101.00M |
|
$262.00M |
|
$460.00M |
|
$464.00M |
|
$464.00M |
|
|
Shareholders Equity |
$464.00M |
127.00M |
|
| Cash Flow Statement Financials | |
$-257.00M |
|
$166.00M |
|
$19.00M |
|
$225.00M |
|
$153.00M |
|
$-72.00M |
|
$34.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.82 |
|
-- |
|
-- |
|
0.18 |
|
0.22 |
|
100.00% |
|
-234.15% |
|
-234.15% |
|
-- |
|
-221.95% |
|
-221.95% |
|
$-257.00M |
|
-- |
|
-- |
|
-- |
|
0.04 |
|
-- |
|
1.14 |
|
79.02 |
|
-19.61% |
|
-19.61% |
|
-9.85% |
|
-16.11% |
|
$3.65 |
|
$-2.04 |
|
$-2.04 |
|